Lelystad, September 25, 2003
Pepscan Systems launches PepChip®, the world's first line of peptide
microarray research products.
Genomics has led to the discovery of about 500 novel protein kinases, which are new major
drug targets in fields like oncology. Unfortunately, current methods for determining the
substrate specificity of these kinases are expensive and labour intensive.
A simple and low cost solution has been created by Pepscan Systems (Lelystad, the
Netherlands): Today PepChip® Kinase is launched at the annual conference of the Society for
Biomolecular Screening (SBS) in Portland (Oregon). PepChip® Kinase combines the
advantage of 1200 known kinase substrates assayed with only 50 microliter, with a very low
background signal. PepChip® Kinase can be used for many applications including substrate
profiling of novel kinases and specificity testing of kinase inhibitors.
Kinase is the first product of the PepChip
family developed, produced and
distributed by Pepscan Systems. The PepChip
family will form a broad line products with
with thousands of useful peptides microarrayed on a chip. Pepscan Systems is the first
company worldwide to make peptide chips available as research product.
Kinase allows scientists to study perform kinase research in house, without the
need to submit samples. Researchers can speed up their research and carefully control the
conditions of their experiment" says Jos Joore Ph. D., VP Array technologies of Pepscan
"I am extremely happy that we now can make kinase profiling available to each scientists at a
fraction of the current costs" says Peter van Dijken, Ph.D. Chief Commercial Officer of
Pepscan Systems. "The coming year we plan to role out a complete family of PepChip®
Pepscan Systems is a Dutch biotech company, based in Lelystad. Pepscan Systems has
proprietary technologies for the design, manufacture and use of peptide-based products and
Pepscan Services offers its proprietary products and services on the basis of fee-for-service
and in risk-sharing collaborations. Pepscan Therapeutics applies these technologies in a
strong internal pipeline of novel immunotherapeutics in oncology.
For further information:
Dr. Jos Joore or Dr. Peter van Dijken
Tel:+ 31320 237200
Fax: +31 320 238120